Yan Changsheng C - OmicsDI

Browse
Submit Data
Databases
API

3 Results

Show all Save search Copy query

Show results for

Unknown (1)
Proteomics (1)
Metabolomics (1)

Organisms

Homo sapiens (1)

Repository

iProX (1)
MetaboLights (1)

Technology Type

Mass spectrometry (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2026 (1)
2025 (1)

Metabolite Name

((4r)-4-((3r,5s,7r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycylglycine (1)
(+)-abscisic acid (1)
(+)-fluprostenol methyl ester (1)
(+-)5,6-DHET (1)
(-)-quebrachitol (1)
(-)-riboflavin (1)
(.+/-.)-2-methylarachidonoyl-2'-fluoroethylamide (1)
(.+/-.)-ethylphenidate (1)
(2-acetyloxy-3,6-diphenylcyclohexyl) acetate (1)
(2r)-3-hydroxyisovaleroylcarnitine (1)
(2r)-5-methoxy-2-methyl-2,3,8,9-tetrahydrofuro[2,3-h]chromen-4-one (1)
(2r,3r,4r,5r,6s)-2-[[(2r,3s,4s,5r,6r)-6-[1,7-bis(4-hydroxyphenyl)heptan-3-yloxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol (1)
(2r,3r,4r,6ar,6bs,8as,11r,12r,12as,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid (1)
(2r,3s,4s,5r,6r)-5-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-2-(hydroxymethyl)-6-(2-phenylethoxy)oxane-3,4-diol (1)
(2r,3s,4s,5r,6r)-6-[1,7-bis(4-hydroxyphenyl)heptan-3-yloxy]-5-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-2-[[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]oxane-3,4-diol (1)
(3.beta.,5.alpha.)-4,4-dimethylcholesta-8,14,24-trien-3-ol (1)
(3r,5r,6r,7s,9s,10r,13r,17r)-17-((r)-5-methoxy-5-oxopentan-2-yl)-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-3,6,7-triyl triacetate (1)
(3s,4s)-5-[(3s,4s)-4,10-dihydroxy-7,9-dimethoxy-3-methyl-3,4-dihydro-1h-benzo[g]isochromen-5-yl]-7,9-dimethoxy-3-methyl-3,4-dihydro-1h-benzo[g]isochromene-4,10-diol (1)
(3s,6r,9s,12r,15s,18r)-3-butan-2-yl-4,10,16-trimethyl-6,9,12,15,18-penta(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone (1)
(3z)-5-[(2,6-dichlorobenzyl)sulfonyl]-3-[(3,5-dimethyl-4-{[(2r)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl}-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one (1)
(4r)-4-((3r,5r,6s,7r,9s,10r,12s,13r,17r)-3,6,7,12-tetrahydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
(4r)-4-((3r,5r,7r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
(4r)-4-((5s,7r,8r,9s,10s,12s,13r,17r)-7,12-dihydroxy-10,13-dimethyl-3-oxohexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
(4r)-4-((5s,7r,9s,10s,13r,14s,17r)-7-hydroxy-10,13-dimethyl-3-oxohexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
(5z,8z,11z,14z,17z-eicosapentaenoyl) coenzyme a (1)
(6s)-5-methyltetrahydrofolic acid (1)
(e)-1-(2,4-dihydroxyphenyl)-3-[4-(3-methylbut-2-enoxy)phenyl]prop-2-en-1-one (1)
(e)-3-(4-acetyloxy-2,3-dihydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl)prop-2-enoic acid (1)
(e)-3-(4-methoxyphenyl)-1-[2,4,6-trimethoxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one (1)
(r)-4-((5r,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3-oxohexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)

Release Date

2022 (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

10

The gut microbiota-butyrate axis restores cardiomyocyte autophagy to alleviate Doxorubicin-induced cardiotoxicity

Abstract

Background Doxorubicin (DOX), an anthracycline chemotherapeutic agent, is widely used for treating various malignancies. However, its clinical application is limited by dose-dependent cardiotoxicity (DOX-induced cardiotoxicity, DIC). Recent studies have shown that the gut microbiot...

2025-09-16 | MTBLS12997 | MetaboLights

Intracardiac echocardiography Chinese expert consensus.

Not available

S-EPMC9584059 | biostudies-literature

Proteomics of Esophageal Squamous Cell Carcinoma Response to anti-PD1 Immunotherapy Response

Immunotherapy has revolutionized cancer treatment, yet many patients do not respond. Here, we profile the proteome and phosphoproteome of clinical pre-treatment samples from 73 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy.

ORGANISM(S): Homo Sapiens

2026-03-31 | PXD076423 |

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

10

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data